Evidence map›Paper›PMID 41896896›Full record

Trial reportBreast cancer research : BCR2026

Lifestyle intervention based on aerobic exercise and Mediterranean diet modulates IGF-1 and its binding proteins in breast cancer survivors.

Giosuè Annibalini, Davide Sisti, Mauro De Santi, Valentina Natalucci, Marta Imperio, Carlo Ferri Marini, Francesco Lucertini, Luciana Vallorani, Roberta Saltarelli, Giulia Baldelli and 7 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04818359 (Movement and Health Beyond Care, MoviS), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04818359 naunknown statusnot on this map

Movement and Health Beyond Care, MoviS: Nutrition and Exercise Educational Programs for Breast Cancer Survivors

TypeinterventionalSponsorUniversity of Urbino "Carlo Bo"Ran2020 to 2025Enrolled172ConditionsBreast Cancer SurvivorsArmsMoviS Training
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Giosuè Annibalini *Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Davide Sisti *Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Mauro De SantiDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy. mauro.desanti@uniurb.it.
Valentina NatalucciDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Marta ImperioDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Carlo Ferri MariniDepartment of Human Movement Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Francesco LucertiniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Luciana ValloraniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Roberta SaltarelliDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Giulia BaldelliDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Simone BarocciClinical Pathology, Hospital Santa Maria della Misericordia di Urbino, Urbino, Italy.
Marco FloriCardiology, Hospital Santa Maria della Misericordia di Urbino, Urbino, Italy.
Vincenzo CatalanoMedical Oncology, Hospital Santa Maria della Misericordia di Urbino, Urbino, Italy.
Marco Bruno Luigi RocchiDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Anna VillariniDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Rita EmiliMedical Oncology, Hospital Santa Maria della Misericordia di Urbino, Urbino, Italy.
Elena BarbieriDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity-related biomarkers such as insulin-like growth factor-1 (IGF-1) may help identify high-risk breast cancer survivors (BCS) who could benefit from lifestyle interventions (LIs). However, the effect of LIs on modulation of IGF-1 levels in BCS remains inconclusive.

methodsFifty inactive BCS were randomized into a control group (CG, n = 26) and an intervention group (IG, n = 24). Both groups received recommendations on exercise and the Mediterranean diet; the IG additionally followed a supervised 3-month aerobic exercise program (MoviS trial, NCT04818359). Associations between baseline and LI-induced changes (∆) in IGF-1, IGF binding protein-1 (IGFBP1) and IGFBP3 levels, along with anthropometric, metabolic, and fitness parameters, were assessed using linear and quadratic models.

resultsBoth groups increased physical activity (MET min/week) and Mediterranean diet adherence (MeDiet score) after the LI, while maximal oxygen uptake (V̇O2max) increased only in the IG. Reductions in BMI, fat mass, insulin levels, HOMA-IR index, total and LDL cholesterol were observed in both groups and were associated with increased IGFBP1 and decreased IGFBP3 levels. Mean IGF-1 levels remained unchanged in both groups. Baseline IGFBP1 was inversely correlated with IGF-1, LDL, BMI, fat mass, and insulin, while baseline IGFBP3 was positively correlated with IGF-1, insulin, and HOMA-IR. Baseline IGF-1 levels were negatively correlated with ∆ IGF-1: participants with IGF-1 ≤ 94.7 ng/mL showed increases, whereas those with IGF-1 ≥ 173.3 ng/mL exhibited decreases post-intervention. Similar trends were found for IGFBP3 but not for IGFBP1. A three-dimensional quadratic model revealed a U-shaped relationship between baseline IGF-1, ∆ IGF-1, and ∆ V̇O2max: improvements in V̇O2max were associated with IGF-1 increase in participants with low baseline IGF-1 and decrease in those with high levels. Conversely, an inverted U-shaped relationship was found between baseline IGF-1, ∆ IGF-1, and ∆ fat mass.

conclusionsThese findings underscore the importance of accounting for IGFBP modulation and baseline heterogeneity in IGF-1 levels when evaluating the efficacy of LIs targeting the IGF-1 system in high-risk BCS. Trial registration ClinicalTrials.gov NCT04818359. Registration Date 26 March 2021.

Indexed as

Breast NeoplasmsCancer SurvivorsDiet, MediterraneanExerciseInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IAdultAgedFemaleHumansLife StyleMiddle AgedIGF1 protein, humanIGFBP1 protein, humanIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IAerobic exerciseBreast cancer survivorsIGF-1IGF-1 binding proteinsLifestyle interventionMediterranean diet

Identifiers

PMID41896896
PMCPMC13151318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.